Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 311

1.

Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial.

Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Ströbel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BRF, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Verschuuren JJGM, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Silvestri NJ, Conwit R, Sonett JR, Jaretzki A 3rd, Newsom-Davis J, Cutter GR; MGTX Study Group.

Lancet Neurol. 2019 Jan 25. pii: S1474-4422(18)30392-2. doi: 10.1016/S1474-4422(18)30392-2. [Epub ahead of print]

PMID:
30692052
2.

Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis.

Kennedy RE, Cutter GR, Fowler ME, Schneider LS.

JAMA Netw Open. 2018 Nov 2;1(7):e184080. doi: 10.1001/jamanetworkopen.2018.4080.

3.

Rationale and design of a single-blind, randomised controlled trial of exercise training for managing learning and memory impairment in persons with multiple sclerosis.

Sandroff BM, Motl RW, Bamman M, Cutter GR, Bolding M, Rinker JR, Wylie GR, Genova H, DeLuca J.

BMJ Open. 2018 Dec 14;8(12):e023231. doi: 10.1136/bmjopen-2018-023231.

4.

Implementation of Occupational Sun Safety at a 2-Year Follow-Up in a Randomized Trial: Comparison of Sun Safe Workplaces Policy Intervention to Attention Control.

Buller DB, Walkosz BJ, Buller MK, Wallis A, Andersen PA, Scott MD, Meenan RT, Cutter GR.

Am J Health Promot. 2018 Nov 26:890117118814398. doi: 10.1177/0890117118814398. [Epub ahead of print]

PMID:
30477333
5.

Use of eHealth and mHealth technology by persons with multiple sclerosis.

Marrie RA, Leung S, Tyry T, Cutter GR, Fox R, Salter A.

Mult Scler Relat Disord. 2019 Jan;27:13-19. doi: 10.1016/j.msard.2018.09.036. Epub 2018 Oct 2.

PMID:
30296732
6.

Short-term disability progression in two multiethnic multiple sclerosis centers in the treatment era.

Kister I, Bacon TE, Cutter GR.

Ther Adv Neurol Disord. 2018 Sep 11;11:1756286418793613. doi: 10.1177/1756286418793613. eCollection 2018.

7.

Medical Rehabilitation: Guidelines to Advance the Field With High-Impact Clinical Trials.

Bamman MM, Cutter GR, Brienza DM, Chae J, Corcos DM, DeLuca S, Field-Fote E, Fouad MN, Lang CE, Lindblad A, Motl RW, Perna CG, Reisman D, Saag KM, Savitz SI, Schmitz KH, Stevens-Lapsley J, Whyte J, Winstein CJ, Michel ME.

Arch Phys Med Rehabil. 2018 Dec;99(12):2637-2648. doi: 10.1016/j.apmr.2018.08.173. Epub 2018 Aug 24.

PMID:
30148997
8.

An introduction to Mendelian randomization with applications in neurology.

Allman PH, Aban IB, Tiwari HK, Cutter GR.

Mult Scler Relat Disord. 2018 Aug;24:72-78. doi: 10.1016/j.msard.2018.06.017. Epub 2018 Jun 20. Review.

PMID:
29960142
9.

Phase-III, randomized controlled trial of the behavioral intervention for increasing physical activity in multiple sclerosis: Project BIPAMS.

Motl RW, Sandroff BM, Wingo BC, McCroskey J, Pilutti LA, Cutter GR, Bollaert RE, McAuley E.

Contemp Clin Trials. 2018 Aug;71:154-161. doi: 10.1016/j.cct.2018.06.017. Epub 2018 Jun 27.

PMID:
29959105
10.

Divergent effects of AKI to CKD models on inflammation and fibrosis.

Black LM, Lever JM, Traylor AM, Chen B, Yang Z, Esman SK, Jiang Y, Cutter GR, Boddu R, George JF, Agarwal A.

Am J Physiol Renal Physiol. 2018 Oct 1;315(4):F1107-F1118. doi: 10.1152/ajprenal.00179.2018. Epub 2018 Jun 13.

PMID:
29897282
11.

Understanding and Preventing Loss to Follow-up: Experiences From the Spinal Cord Injury Model Systems.

Kim H, Cutter GR, George B, Chen Y.

Top Spinal Cord Inj Rehabil. 2018 Spring;24(2):97-109. doi: 10.1310/sci2402-97.

PMID:
29706754
12.

Phase II Randomized Controlled Trial of Constraint-Induced Movement Therapy in Multiple Sclerosis. Part 1: Effects on Real-World Function.

Mark VW, Taub E, Uswatte G, Morris DM, Cutter GR, Adams TL, Bowman MH, McKay S.

Neurorehabil Neural Repair. 2018 Mar;32(3):223-232. doi: 10.1177/1545968318761050.

PMID:
29668399
13.

Occupational Therapy Treatment to Improve Upper Extremity Function in Individuals with Early Systemic Sclerosis: A Pilot Study.

Murphy SL, Barber MW, Homer K, Dodge C, Cutter GR, Khanna D.

Arthritis Care Res (Hoboken). 2018 Nov;70(11):1653-1660. doi: 10.1002/acr.23522.

PMID:
29381834
14.

Defining standard enzymatic dissociation methods for individual brains and spinal cords in EAE.

Hussain RZ, Miller-Little WA, Doelger R, Cutter GR, Loof N, Cravens PD, Stüve O.

Neurol Neuroimmunol Neuroinflamm. 2018 Jan 17;5(2):e437. doi: 10.1212/NXI.0000000000000437. eCollection 2018 Mar.

15.

Treatment satisfaction and bothersome bladder, bowel, sexual symptoms in multiple sclerosis.

Wang G, Marrie RA, Fox RJ, Tyry T, Cofield SS, Cutter GR, Salter A.

Mult Scler Relat Disord. 2018 Feb;20:16-21. doi: 10.1016/j.msard.2017.12.006. Epub 2017 Dec 14.

PMID:
29275057
16.

Perspectives on marijuana use and effectiveness: A survey of NARCOMS participants.

Cofield SS, Salter A, Tyry T, Crowe C, Cutter GR, Fox RJ, Marrie RA.

Neurol Clin Pract. 2017 Aug;7(4):333-343. doi: 10.1212/CPJ.0000000000000383.

17.

Prevalence of Sun Protection at Outdoor Recreation and Leisure Venues at Resorts in North America.

Walkosz BJ, Scott MD, Buller DB, Andersen PA, Beck L, Cutter GR.

Am J Health Educ. 2017;48(2):90-99. doi: 10.1080/19325037.2016.1271755. Epub 2017 Mar 10.

18.

Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years.

Lublin FD, Cofield SS, Cutter GR, Gustafson T, Krieger S, Narayana PA, Nelson F, Salter AR, Wolinsky JS.

Mult Scler Relat Disord. 2017 Nov;18:95-102. doi: 10.1016/j.msard.2017.09.012. Epub 2017 Sep 23.

19.

Trigeminal Neuralgia Commonly Precedes the Diagnosis of Multiple Sclerosis.

Fallata A, Salter A, Tyry T, Cutter GR, Marrie RA.

Int J MS Care. 2017 Sep-Oct;19(5):240-246. doi: 10.7224/1537-2073.2016-065.

20.

Pedestrian safety in patients with Parkinson's disease: A case-control study.

Ford KJ, Joop A, Memon RA, Wood KH, Ball K, Cutter GR, Schwebel DC, Amara AW.

Mov Disord. 2017 Dec;32(12):1748-1755. doi: 10.1002/mds.27124. Epub 2017 Oct 4.

21.

Author response: High hypothetical interest in physician-assisted death in multiple sclerosis.

Marrie RA, Salter A, Tyry T, Cutter GR, Fox RJ.

Neurology. 2017 Sep 26;89(13):1429-1430. doi: 10.1212/WNL.0000000000004437. No abstract available.

PMID:
28947584
22.

Prevalence odds ratio versus prevalence ratio: choice comes with consequences.

Tamhane AR, Westfall AO, Burkholder GA, Cutter GR.

Stat Med. 2017 Oct 15;36(23):3760. doi: 10.1002/sim.7375. Epub 2017 Jul 6. No abstract available.

PMID:
28872254
23.

The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.

LaRocca NG, Hudson LD, Rudick R, Amtmann D, Balcer L, Benedict R, Bermel R, Chang I, Chiaravalloti ND, Chin P, Cohen JA, Cutter GR, Davis MD, DeLuca J, Feys P, Francis G, Goldman MD, Hartley E, Kapoor R, Lublin F, Lundstrom G, Matthews PM, Mayo N, Meibach R, Miller DM, Motl RW, Mowry EM, Naismith R, Neville J, Panagoulias J, Panzara M, Phillips G, Robbins A, Sidovar MF, Smith KE, Sperling B, Uitdehaag BM, Weaver J; Multiple Sclerosis Outcome Assessments Consortium (MSOAC).

Mult Scler. 2018 Oct;24(11):1469-1484. doi: 10.1177/1352458517723718. Epub 2017 Aug 11.

24.

Interactions between cannabidiol and commonly used antiepileptic drugs.

Gaston TE, Bebin EM, Cutter GR, Liu Y, Szaflarski JP; UAB CBD Program.

Epilepsia. 2017 Sep;58(9):1586-1592. doi: 10.1111/epi.13852. Epub 2017 Aug 6.

25.

Comparative utility of disability progression measures in PPMS: Analysis of the PROMiSe data set.

Koch MW, Cutter GR, Giovannoni G, Uitdehaag BMJ, Wolinsky JS, Davis MD, Steinerman JR, Knappertz V.

Neurol Neuroimmunol Neuroinflamm. 2017 May 10;4(4):e358. doi: 10.1212/NXI.0000000000000358. eCollection 2017 Jul.

26.

Laquinimod has no effects on brain volume or cellular CNS composition in the F1 3xTg-AD/C3H mouse model of Alzheimer's disease.

Hussain RZ, Miller-Little WA, Lambracht-Washington D, Jaramillo TC, Takahashi M, Zhang S, Fu M, Cutter GR, Hayardeny L, Powell CM, Rosenberg RN, Stüve O.

J Neuroimmunol. 2017 Aug 15;309:100-110. doi: 10.1016/j.jneuroim.2017.05.017. Epub 2017 May 26.

PMID:
28601278
27.

Erratum to: Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot study.

Wright NC, Foster PJ, Mudano AS, Melnick JA, Lewiecki EM, Shergy WJ, Curtis JR, Cutter GR, Danila MI, Kilgore ML, Lewis EC, Morgan SL, Redden DT, Warriner AH, Saag KG.

Osteoporos Int. 2017 Aug;28(8):2505. doi: 10.1007/s00198-017-4105-1. No abstract available.

PMID:
28593448
28.

Challenging Assumptions About African American Participation in Alzheimer Disease Trials.

Kennedy RE, Cutter GR, Wang G, Schneider LS.

Am J Geriatr Psychiatry. 2017 Oct;25(10):1150-1159. doi: 10.1016/j.jagp.2017.04.013. Epub 2017 Apr 25.

29.

Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot study.

Wright NC, Foster PJ, Mudano AS, Melnick JA, Lewiecki EM, Shergy WJ, Curtis JR, Cutter GR, Danila MI, Kilgore ML, Lewis EC, Morgan SL, Redden DT, Warriner AH, Saag KG.

Osteoporos Int. 2017 Aug;28(8):2495-2503. doi: 10.1007/s00198-017-4073-5. Epub 2017 May 24. Erratum in: Osteoporos Int. 2017 Jun 7;:.

30.

A contemporary profile of primary progressive multiple sclerosis participants from the NARCOMS Registry.

Salter A, Thomas NP, Tyry T, Cutter GR, Marrie RA.

Mult Scler. 2018 Jun;24(7):951-962. doi: 10.1177/1352458517711274. Epub 2017 May 19.

PMID:
28524746
31.

The Virtual Short Physical Performance Battery: Psychometric Properties and Validation in Older Adults With Multiple Sclerosis.

Bollaert RE, Marsh AP, Cutter GR, Motl RW.

J Appl Gerontol. 2017 May 1:733464817709532. doi: 10.1177/0733464817709532. [Epub ahead of print]

PMID:
28506093
32.

Neurocognitive Predictors of Declining Financial Capacity in Persons with Mild Cognitive Impairment.

Niccolai LM, Triebel KL, Gerstenecker A, McPherson TO, Cutter GR, Martin RC, Marson DC.

Clin Gerontol. 2017 Jan-Feb;40(1):14-23. doi: 10.1080/07317115.2016.1228022. Epub 2016 Sep 1.

33.

Upper limb impairment is associated with use of assistive devices and unemployment in multiple sclerosis.

Marrie RA, Cutter GR, Tyry T, Cofield SS, Fox R, Salter A.

Mult Scler Relat Disord. 2017 Apr;13:87-92. doi: 10.1016/j.msard.2017.02.013. Epub 2017 Feb 20.

PMID:
28427709
34.

Association Between Early Childhood Caries and Colonization with Streptococcus mutans Genotypes From Mothers.

Childers NK, Momeni SS, Whiddon J, Cheon K, Cutter GR, Wiener HW, Ghazal TS, Ruby JD, Moser SA.

Pediatr Dent. 2017 Mar 15;39(2):130-135.

35.

Evaluating risk factors for chronic kidney disease in pediatric patients with sickle cell anemia.

Lebensburger JD, Cutter GR, Howard TH, Muntner P, Feig DI.

Pediatr Nephrol. 2017 Sep;32(9):1565-1573. doi: 10.1007/s00467-017-3658-8. Epub 2017 Apr 5.

36.

High hypothetical interest in physician-assisted death in multiple sclerosis.

Marrie RA, Salter A, Tyry T, Cutter GR, Cofield S, Fox RJ.

Neurology. 2017 Apr 18;88(16):1528-1534. doi: 10.1212/WNL.0000000000003831. Epub 2017 Mar 15.

PMID:
28298551
37.

Publication outcomes of abstracts from the American Society of Hematology Annual Meeting.

Baddam S, Cutter GR, Wolfson JA, Friedman GK, Lebensburger JD.

Am J Hematol. 2017 May;92(5):E81-E83. doi: 10.1002/ajh.24695. Epub 2017 Mar 20. No abstract available.

38.

Effect of an intervention on observed sun protection by vacationers in a randomized controlled trial at North American resorts.

Buller DB, Andersen PA, Walkosz BJ, Scott MD, Beck L, Cutter GR.

Prev Med. 2017 Jun;99:29-36. doi: 10.1016/j.ypmed.2017.01.014. Epub 2017 Feb 9.

39.

Potentially Modifiable Factors Associated With Physical Activity in Individuals With Multiple Sclerosis.

Reider N, Salter AR, Cutter GR, Tyry T, Marrie RA.

Res Nurs Health. 2017 Apr;40(2):143-152. doi: 10.1002/nur.21783. Epub 2017 Feb 6.

PMID:
28165143
40.

Continuous Electroencephalography (cEEG) Monitoring and Outcomes of Critically Ill Patients.

Khawaja AM, Wang G, Cutter GR, Szaflarski JP.

Med Sci Monit. 2017 Feb 4;23:649-658.

41.

Randomized trial of thymectomy in myasthenia gravis.

Wolfe GI, Kaminski HJ, Sonnett JR, Aban IB, Kuo HC, Cutter GR.

J Thorac Dis. 2016 Dec;8(12):E1782-E1783. doi: 10.21037/jtd.2016.12.80. No abstract available.

42.

Clinical trials: To catch a crook, you might try statistics.

Cutter GR.

Nat Rev Neurol. 2017 Jan;13(1):9-10. doi: 10.1038/nrneurol.2016.194. Epub 2016 Dec 16. No abstract available.

PMID:
27982044
43.

Randomized Trial of Thymectomy in Myasthenia Gravis.

Wolfe GI, Kaminski HJ, Cutter GR.

N Engl J Med. 2016 Nov 17;375(20):2006-2007. doi: 10.1056/NEJMc1611704. No abstract available.

PMID:
27959593
44.

Sustained High Level of Healthcare Worker Adherence With Hand Hygiene Practice Recommendations Using the Patient-as-Observer Approach in the Ambulatory Setting.

Lee RA, Cutter GR, Pate JL, Boohaker E, Camins BC.

Infect Control Hosp Epidemiol. 2016 Dec;37(12):1496-1498. Epub 2016 Oct 4.

PMID:
27697087
45.

Baseline EDSS proportions in MS clinical trials affect the overall outcome and power: A cautionary note.

Wang G, Cutter GR, Cofield SS, Lublin F, Wolinsky JS, Gustafson T, Krieger S, Salter A.

Mult Scler. 2017 Jun;23(7):982-987. doi: 10.1177/1352458516670733. Epub 2016 Sep 28.

46.

Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree.

Cutter GR, Knappertz V, Sasson N, Ladkani D.

BMC Neurol. 2016 Sep 17;16:176. doi: 10.1186/s12883-016-0702-4.

47.

Randomized Trial of Thymectomy in Myasthenia Gravis.

Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Ströbel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BR, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Garcia Ramos GS, Verschuuren JJ, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Conwit R, Odenkirchen J, Sonett JR, Jaretzki A 3rd, Newsom-Davis J, Cutter GR; MGTX Study Group.

N Engl J Med. 2016 Aug 11;375(6):511-22. doi: 10.1056/NEJMoa1602489. Erratum in: N Engl J Med. 2017 May 25;376(21):2097. [Dosage error in article text].

48.

Long-term evolution of multiple sclerosis disability in the treatment era.

University of California, San Francisco MS-EPIC Team:, Cree BA, Gourraud PA, Oksenberg JR, Bevan C, Crabtree-Hartman E, Gelfand JM, Goodin DS, Graves J, Green AJ, Mowry E, Okuda DT, Pelletier D, von Büdingen HC, Zamvil SS, Agrawal A, Caillier S, Ciocca C, Gomez R, Kanner R, Lincoln R, Lizee A, Qualley P, Santaniello A, Suleiman L, Bucci M, Panara V, Papinutto N, Stern WA, Zhu AH, Cutter GR, Baranzini S, Henry RG, Hauser SL.

Ann Neurol. 2016 Oct;80(4):499-510. doi: 10.1002/ana.24747. Epub 2016 Aug 13.

49.

Prevalence odds ratio versus prevalence ratio: choice comes with consequences.

Tamhane AR, Westfall AO, Burkholder GA, Cutter GR.

Stat Med. 2016 Dec 30;35(30):5730-5735. doi: 10.1002/sim.7059. Epub 2016 Jul 26. Erratum in: Stat Med. 2017 Oct 15;36(23 ):3760.

50.

T cell cytokine signatures: Biomarkers in pediatric multiple sclerosis.

Cala CM, Moseley CE, Steele C, Dowdy SM, Cutter GR, Ness JM, DeSilva TM.

J Neuroimmunol. 2016 Aug 15;297:1-8. doi: 10.1016/j.jneuroim.2016.04.015. Epub 2016 Apr 30.

Supplemental Content

Loading ...
Support Center